ClinicalTrials.gov
public full text
Public Domain
Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis
The objective of this trial is to assess the efficacy and safety of CNM-Au8 as a remyelinating treatment for vision-impairing MS lesions in participants who have chronic vision impairment as a result of Relapsing-Remitting Multiple Sclerosis. The primary endpoint is to assess the efficacy and safety of CNM-Au8 as a remyelinating therapy in patients with stable RMS. The secondary endpoint is Change in Functional Composite Responder Analysis Score from Baseline to Week 24.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Applications of Nanotechnology in Multiple Sclerosis by Respiratory Samples#230428
- Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis#906918
- GER-009-06-AVX Early Therapy in Multiple Sclerosis#841243
- Association of Peripapillary Retinal Nerve Fibre Layer Thickness with Disability and MRI Findings in Multiple Sclerosis: A Retrospective Single-Centre Cohort Study#231277
- Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)#968452
Record · ID 979190
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive